Talazoparib for Castration

Phase-Based Progress Estimates
Castration+2 More
Talazoparib - Drug
What conditions do you have?

Study Summary

This trial is testing the safety and effectiveness of combining these two drugs to treat prostate cancer.

Eligible Conditions
  • Castration
  • Malignant Neoplasms

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Castration

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: Enrollment up to 2 years

Year 2
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0
Overall response rate (ORR)
Day 28
Rate of Dose Limiting Toxicity (DLT)

Trial Safety

Safety Progress

1 of 3

Other trials for Castration

Trial Design

2 Treatment Groups

Dose Escalation Talazoparib + Tazemetostat
1 of 2
Dose Expansion Talazoparib + Tazemetostat
1 of 2
Experimental Treatment

38 Total Participants · 2 Treatment Groups

Primary Treatment: Talazoparib · No Placebo Group · Phase 1

Dose Escalation Talazoparib + TazemetostatExperimental Group · 2 Interventions: Talazoparib, Tazemetostat · Intervention Types: Drug, Drug
Dose Expansion Talazoparib + TazemetostatExperimental Group · 2 Interventions: Talazoparib, Tazemetostat · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: enrollment up to 2 years

Who is running the clinical trial?

PfizerIndustry Sponsor
4,260 Previous Clinical Trials
7,104,881 Total Patients Enrolled
Epizyme, Inc.Industry Sponsor
30 Previous Clinical Trials
2,893 Total Patients Enrolled
Dana-Farber Cancer InstituteLead Sponsor
1,012 Previous Clinical Trials
393,321 Total Patients Enrolled
Atish Choudhury, MD PhDPrincipal Investigator - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Eligibility Criteria

Age 18+ · Male Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a performance status of 0 or 1 (i.e., no symptoms or mild symptoms).
You have a history of progression on at least one novel hormonal therapy in either the hormone-sensitive or castration-resistant disease setting.
A rising PSA value indicates prostate cancer.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 23rd, 2021

Last Reviewed: October 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.